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Abstract
Falcipain-2, a papain family cysteine protease of the malaria parasite Plasmodium falciparum, plays a key role in parasite
hydrolysis of hemoglobin and is a potential chemotherapeutic target. As with many proteases, falcipain-2 is synthesized as a
zymogen, and the prodomain inhibits activity of the mature enzyme. To investigate the mechanism of regulation of
falcipain-2 by its prodomain, we expressed constructs encoding different portions of the prodomain and tested their ability
to inhibit recombinant mature falcipain-2. We identified a C-terminal segment (Leu155–Asp243) of the prodomain, including
two motifs (ERFNIN and GNFD) that are conserved in cathepsin L sub-family papain family proteases, as the mediator of
prodomain inhibitory activity. Circular dichroism analysis showed that the prodomain including the C-terminal segment, but
not constructs lacking this segment, was rich in secondary structure, suggesting that the segment plays a crucial role in
protein folding. The falcipain-2 prodomain also efficiently inhibited other papain family proteases, including cathepsin K,
cathepsin L, cathepsin B, and cruzain, but it did not inhibit cathepsin C or tested proteases of other classes. A structural
model of pro-falcipain-2 was constructed by homology modeling based on crystallographic structures of mature falcipain-2,
procathepsin K, procathepsin L, and procaricain, offering insights into the nature of the interaction between the prodomain
and mature domain of falcipain-2 as well as into the broad specificity of inhibitory activity of the falcipain-2 prodomain.
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Introduction
Malaria is the most important parasitic disease in the world.
Plasmodium falciparum, the most virulent human malaria parasite, is
responsible for hundreds of millions of illnesses and about one
million deaths each year (1). The control of malaria is hindered by
increasing resistance to available drugs, making it important to
develop new drugs to treat this disease. Among potential new
targets for antimalarial chemotherapy are falcipain cysteine
proteases (2). The best characterized of these proteases, falci-
pain-2 and falcipain-3, play key roles in the hydrolysis of
hemoglobin by intraerythrocytic parasites (3–5). Inhibitors of
falcipains demonstrate potent in vitro and in vivo antimalarial
activity, and these proteases are the targets of efforts to develop
novel cysteine protease inhibitors as new antimalarial drugs (2).
Falcipains are cathepsin L-like papain-family cysteine proteases
(2). Features shared with other proteases of this sub-family include
a catalytic domain of ,30 kDa with conserved active site amino
acid residues and a prodomain with potent enzyme inhibitory
activity (6). We have characterized a number of unusual features of
falcipains. First, folding of the mature protease is mediated by a
short (14 amino acids for falcipain-2) N-terminal extension, rather
than the enzyme prodomain (6, 7). Second, a 10 amino acid
insertion near the C-terminus mediates interaction of the mature
domain with its principal substrate, hemoglobin, and with the
prodomain (8). Third, the prodomain does not have a typical
signal sequence, but contains a membrane-spanning domain that
predicts a type II integral membrane protein. Fourth, the falcipain
prodomain is much larger than that of most other described
papain-family proteases, with downstream sequence similar to
papain and related enzymes, but unique upstream regions that
mediate trafficking of falcipain-2 to the food vacuole, the site of
hydrolysis of hemoglobin (9).
Considering its importance as a potential drug target, we were
interested in evaluating the features of the falcipain-2 prodomain
that mediate enzyme inhibition. We hypothesized that the
inhibitory function is mediated by the downstream portion of
the prodomain, which has amino acid sequence similar to that of
other papain family proteases. In this region, cathepsin L-like
papain family proteases, including falcipains, contain a number of
conserved residues that appear to mediate interaction between the
prodomain and mature protease (10), including six amino acids
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(ERFNIN in papain) spanning nineteen residues (11, 12) and,
further downstream, four conserved amino acids (GNFD in
papain) spanning seven residues (13). Conservative substitutions at
these motifs are common; the sequences are ERWNIN and ANFD
in cathepsin L and DRWNIN and ANLD in cathepsin K. In
cathepsin L, these residues appear to stabilize the prodomain
structure through the formation of salt bridges (14). To determine
the roles of these conserved amino acids and other portions of the
falcipain-2 prodomain in enzyme inhibition, we expressed the
prodomain and a series of truncated fragments, and evaluated
their inhibitory activity (15). Our results define a 61 amino acid
minimum inhibitory domain, which includes the ERFNIN and
GNFD motifs, that strongly inhibits falcipain-2 and many other
cysteine proteases. Modeling of the falcipain-2 prodomain suggests
that the prodomain covers the enzyme active site, and thereby
inhibits activity by preventing substrate access.
Results
Identification of the Inhibitory Domain of Falcipain-2
Falcipain-2 and homologs from related plasmodia have much
larger prodomains than those of most papain-family proteases.
The upstream portion of the falcipain-2 prodomain bears no
obvious resemblance to sequences of non-plasmodial proteases,
and mediates enzyme trafficking to the parasite food vacuole (9).
In contrast, the downstream portion of the falcipain-2 prodomain
is similar to that of papain, and in particular to the cathepsin L
sub-family of papain-family proteases (Fig. 1). Sequence identity
for this region between falcipain-2 and human cathepsin L is
,21%, and residues that have been identified as playing key roles
in the functions of papain family prodomains are generally
conserved in falcipain-2 and plasmodial homologs. The well
characterized ERFNIN and GNFD domains (10), which contrib-
ute to proenzyme stability, are both fully conserved in falcipain-3,
but falcipain-2 differs from the consensus sequence at one
ERFNIN (IRV) and one GNFD (GRE) residue. Two highly
conserved Trp residues (at positions 19 and 22, of procathepsin L),
which also contribute to the stability of cathepsin L sub-family
proteases (12), are each replaced by Phe in both falcipain-2 and
falcipain-3 (Fig. 1; falcipain-2 positions 165 and 168).
We previously showed that the prodomain of falcipain-2 is a
potent reversible inhibitor of the protease (6). To characterize the
requirements for inhibition, we expressed a series of prodomain
fragments in E. coli (Figure S1) and evaluated inhibition of
falcipain-2 by each of the fragments (Fig. 2). All peptides were
soluble in the buffers used for our experiments and stable under
our experimental conditions. As we hypothesized, the large
upstream portion of the prodomain, which includes a transmem-
brane domain flanked by cytosolic and lumenal segments, and
which mediates trafficking of falcipain-2 to the food vacuole (9), is
not required for enzyme inhibition. Inhibitory potency was the
same for a prodomain construct lacking only the upstream
cytosolic and transmembrane domains (Tyr54-Asp243) and for
constructs lacking the upstream 104 (Ser105-Asp243), 126 (Leu127-
Asp243), or 154 (Leu155-Asp243) amino acids of the prodomain
(Fig. 2). All of these constructs were very potent inhibitors of
falcipain-2, with Ki , 1 nM. Removal of the 27 C-terminal amino
acids of the prodomain (Tyr54-Asp216) did not affect inhibitory
potency, but removal of the 37 C-terminal amino acids (Tyr54-
Leu206) led to an ,2000-fold loss of inhibitory potency, and
removal of the 63 C-terminal amino acids (Tyr54-Asn180) led to a
complete loss of inhibitory activity. A peptide spanning the
ERFNIN and GNFD motifs (Tyr176-Asp216) demonstrated no
inhibitory activity. These results allow identification of a minimum
inhibitory domain for falcipain-2 (Leu155-Asp216), which includes
two hydrophobic residues (Phe165 and Phe168 in falcipain-2; Phe182
and Phe185 in falcipain-3) and the ERFNIN and GNFD motifs, all
of which are highly conserved among other cathepsin L sub-family
proteases. We could not directly test the inhibitory activity of this
minimum inhibitory peptide, as production of the recombinant
peptide was unsuccessful.
Inhibitory Activity of the Falcipain-2 Prodomain Against
Other Cysteine Proteases
Cathepsin L sub-family protease prodomains generally inhibit
only closely related proteases. For example, the prodomains of
cathepsin L, cathepsin K, and cathepsin S are each potent
inhibitors of all three proteases, but not of cathepsin B (10). In
contrast, the falcipain-2 prodomain had a rather broad inhibitory
specificity, with inhibition of the falcipain-2 homolog from
Figure 1. Alignment of C-terminal amino acid residues of the prodomains of falcipain-2 and related cysteine proteases. The
sequences of falcipain-2 (FP2), falcipain-3 (FP3), berghepain-2 (BP2), human cathepsin K (Cath K), human cathepsin L (Cath L), human cathepsin B
(Cath B), and papain were aligned using Expassy (European Bioinformatics Institute). Amino acids comprising the ERFNIN and GNFD motifs are
labeled with stars, and conserved hydrophobic residues are indicated by arrows. Amino acids that are identical or similar to those of falcipain-2 are
highlighted.
doi:10.1371/journal.pone.0005694.g001
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Plasmodium berghei (berghepain-2), the Trypanosoma cruzi protease
cruzain, cathepsin L, and cathepsin B (Fig. 3). The only tested
papain-family cysteine protease that was not inhibited was the
dipeptidyl peptidase cathepsin C. The aspartic protease pepsin,
serine protease a-chymotrypsin, and metalloprotease collagenase
were not inhibited by the falcipain-2 prodomain.
Structural Explanation for Inhibitory Activity of Falcipain-
2 Prodomain Fragments
Structure-function studies identified a discrete portion of the
falcipain-2 prodomain required for inhibition of the cognate mature
protease. Prior work with other cathepsin L sub-family proteases
suggests key roles for conserved hydrophobic amino acids as well as
the ERFNIN and GNFD motifs in maintaining prodomain
structure (10). We explored the roles of different domains in
maintaining prodomain structure by circular dichroism analysis
(Fig. 4). Secondary structure was seen in a fragment with potent
inhibitory activity (Leu155-Asp243), but not in two larger constructs
that lacked any sequence downstream of the ERFNIN and GNFD
motifs (Tyr54-Leu206; Tyr54-Asn180) or in a peptide spanning the
ERFNIN and GNFD motifs (Tyr176-Asp216). These results indicate
that the ERFNIN and GNFD motifs and an upstream region
including conserved Phe residues are required for proper folding or
maintenance of secondary structure of the prodomain.
Homology Modeling of Profalcipain-2
To explain the role of profalcipain-2 motifs in enzyme
inhibition, we modeled the structure of the target falcipain-2
Figure 2. Inhibitory activity of profalcipain-2 constructs. The domains of falcipain-2 and the studied constructs are represented
diagrammatically. Abbreviations: Cyto, cytosolic domain; TM, transmembrane domain; Hb, hemoglobin. The residues contained in each construct are
shown, and the inhibitory capacity of mature falcipain-2 for each construct is indicated. The data provided are the Ki values for each polypeptide
construct. Results are from two experiments, each performed in duplicate.
doi:10.1371/journal.pone.0005694.g002
Figure 3. Inhibition of different proteases by the prodomain of
falcipain-2. The inhibition of falcipain-2 (FP2), falcipain-29 (FP29),
falcipain-3 (FP3), berghepain-2 (BP2), cruzain, human cathepsin B (Cath
B), human cathepsin L (Cath L), bovine cathepsin C (Cath C), pepsin, a-
chymotrypsin (a-Chymo), and collagenase was measured as described
in Experimental Procedures. In each case activity was measured with
and without the prodomain and the percentage inhibition calculated.
Error bars represent standard deviations from two experiments, each
performed in duplicate.
doi:10.1371/journal.pone.0005694.g003
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using the crystallographic structures of several papain-family
cysteine proteases as templates. We used the software MOD-
ELLER-9v4 (16) to construct a homology model of profalcipain-2
(Fig. 5a), which aligned to mature falcipain-2, procathepsin L,
procathepsin K, and procaricain at sequence identities of 100%
(by definition, aligned with the sequence of the mature domain
only), 30.6%, 30.9%, and 32.1% respectively (14, 20–24). The
model was evaluated with DOPE (Discrete Optimized Protein
Energy), a pairwise atomic distance statistical potential that
assesses atomic distances in a model relative to those observed in
many known protein structures (17). The DOPE Z-score of the
model (20.99) is similar to the Z-scores of all templates (cathepsin
L: 21.62; mature falcipain-2: 21.13; procathepsin K 20.95;
procaricain 21.25); generally, a Z-score of 21 or less indicates a
relatively accurate model, with more than 80% of its Ca atoms
within 3.5 A˚ of their correct positions (17). Additionally, a separate
assessment technique, TSVMod, was applied. This method
predicts the native overlap (defined as the fraction of a-carbon
atoms within 3.5 A˚ of the native structure) of a homology model in
the absence of a solved structure using support vector machine
learning (18, 19). The model’s predicted native overlap (0.85) was
similar to that of a model of mature falcipain-2 built using the
mature sections of the above templates, indicating the falcipain-2
prodomain does not contribute significantly disproportionately to
the overall model error. This assessment suggests that the fold of
the profalcipain-2 model is correct despite the relatively low
sequence identity between the falcipain-2 prodomain and the
templates.
The Profalcipain-2 Model Suggests that the Conserved
Residues Provide Stability to the Overall Fold
We examined the homology model for possible interactions
involving residues in the conserved motifs. Several of these
residues are highlighted in Fig. 5b. (i) The charged pair Arg185 and
Glu221 appears to form a salt bridge. (ii) Glu210 from the GNFD
motif may form a separate salt bridge with Lys403 in the mature
domain. (iii) Phe214 may participate in non-polar interactions, and
possibly p-bond stacking, with two tryptophan residues on the
mature domain, Trp449 and Trp453. All of these interactions are
also present in at least one of the templates used to build the
model, although none of them is conserved across all templates.
The Falcipain-2 Prodomain Appears to Block Substrates
from Entering the Cathepsin B Active Site
A separate homology model was constructed in which the
falcipain-2 prodomain and cathepsin-B mature domain were
modeled as a complex (Fig. 6a). The model was built based on
an alignment of profalcipain-2 at 31.2% sequence identity with
the crystallographic structure of procathepsin B (25, 26). The
model received a DOPE Z score of 20.87, and a TSVMod
native overlap prediction of 0.82. These scores indicate that the
overall fold is correct; poor scores would have suggested that
there were significant errors in the modeled structure of the
prodomain, and in that case the model would not have
resembled the structures of the templates on which it was
based. The model suggests that the prodomain of falcipain-2
binds mature cathepsin B in a manner similar to that observed
in papain family zymogens, inhibiting catalytic activity by
blocking substrate access to the active site. (Fig. 6b). While no
structure has been solved for a propeptide in complex with an
inhibited mature enzyme, it is likely that these propeptides bind
to the enzymes in a conformation resembling the zymogen form
(14, 25–27). This hypothesis is reflected in the model, which by
construction is similar to its templates, and displays favorable
stereochemistry and non-bonded atom distances as evaluated by
MODELLER and DOPE.
Differences Between the Prodomains of Falcipain-2 and
Cathepsin L
Cathepsin B activity is inhibited by the prodomain of falcipain-2
(Fig. 3) but not cathepsin L (10). To examine the structural basis of
this selectivity, we compared the sequences and structures of these
two proteins. Several differences were of note (Fig. 7). First, while
the procathepsin L a1 helix clashes with the occluding loop region
of mature cathepsin B, thus preventing binding, the equivalent
helix in falcipain-2 does not. Second, Phe186 in profalcipain-2
participates in polar interactions with Phe165 and Phe168; in
procathepsin K and procathepsin L, Phe186 is replaced by Arg.
Third, a multiple sequence alignment reveals a conserved motif
(LMNNAEHIN in falcipain-2) in the plasmodial proteases
falcipain-2, falcipain-3, and berghepain-2 that represents an
insertion relative to the sequences of procathepsin K and
procathepsin L (Fig. 1). Finally, an apparent salt bridge
(interaction not shown) is formed between Glu210 in the
falcipain-2 prodomain and Lys184 in mature cathepsin B; Glu210
of falcipain-2 (which has replaced Gly in the GNFD motif) is
replaced by Ala in cathepsin L and cathepsin K. Taken together,
differences between modeled interactions for the cathepsin B
mature domain with procathepsin L or profalcipain-2 appear to
describe the structural basis for the observed selective inhibition of
cathepsin B activity by profalcipain-2.
Discussion
We evaluated features of the falcipain-2 prodomain that
mediate enzyme inhibition. Our data show that only an
,11 kDa C-terminal region of the prodomain is required for
potent inhibition of the protease. The region includes two
hydrophobic residues (both Phe in falcipain-2) and the ERFNIN
and GNFD motifs, all of which are conserved among cathepsin L-
like papain family proteases. The falcipain-2 prodomain also
inhibited other papain family cysteine proteases, including similar
cathepsin L sub-family proteases and the more distantly related
Figure 4. Circular dichroism analysis of prodomain constructs.
Different falcipain-2 prodomain constructs (200 mg/ml) were incubated
in 20 mM sodium phosphate, pH 5.8, and absorbance between 195 and
240 nm was measured.
doi:10.1371/journal.pone.0005694.g004
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cathepsin B. We explored the relevance of conserved falcipain-2
motifs by circular dichroism; the conserved residues were required
to maintain the secondary structure of the prodomain. Thus, the
first prerequisite for inhibitory activity was appropriate secondary
structure. We also constructed a homology model of profalcipain-2
to help explain the observed experimental results. The model
identified potential interactions between the inhibitory portion of
the prodomain and mature falcipain-2 that appear to explain the
inhibitory activity, and also the ability of the prodomain of
falcipain-2, but not that of the related protease cathepsin L, to
inhibit cathepsin B. Taken together, our results identify and
structurally characterize a minimum inhibitory domain of the
falcipain-2 prodomain, offering a starting point for new consid-
erations for the inhibition of key proteases of malaria parasites.
Indeed, small molecules that inhibit falicipains via interactions
independent of the active site might offer highly specific
antimalarials without detrimental effects due to inhibition of host
cysteine proteases.
Results of structure-function studies were straightforward. As
expected, the upstream portion of the falcipain-2 prodomain,
which mediates protein trafficking (9), was not required for
inhibitory activity. Indeed, only a small portion of the prodomain
Figure 5. Homology model of profalcipain-2. (a) Model created using MODELLER 9v4. The 160 N-terminal residues of the prodomain are
not included in the model. The prodomain (cyan) runs up the face of the mature enzyme (purple; catalytic triad residues in orange) before forming a-
helices containing the conserved ERFNIN and GNFD motifs (yellow). (b) Close-up of several predicted interactions between the mature
protease and the ERFNIN (R185) and GNFD (E210; F214) motifs. Blue dashed lines indicate presumed stabilizing interactions (both electrostatic
and hydrophobic) between residues. The structure has been rotated 180 degrees around the vertical axis from its representation in figure 5a.
doi:10.1371/journal.pone.0005694.g005
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(Leu155-Asp216) was required for sub-nanomolar inhibition of the
mature enzyme. We did not demonstrate inhibition by the isolated
Leu155-Asp216 peptide, as production of this peptide proved difficult,
but consideration of inhibition by a number of overlapping
constructs (Fig. 2) clearly demonstrates that this peptide is
sufficient for inhibition of falcipain-2. Circular dichroism studies
suggested that the limits of the minimum inhibitory domain are
dictated by requirements for appropriate folding and maintenance
of a secondary structure for the inhibitory portion of the
prodomain.
Figure 6. Model rationalizing the inhibition of cathepsin B by the falcipain-2 prodomain. (a) Model of the falcipain-2 prodomain
(red) and mature cathepsin B (blue; catalytic triad residues in yellow). The prodomain binds to cathepsin B in a similar fashion as zymogens
of other cysteine proteases, including procathepsin L and procathepsin B. (b) Structural overlay of mature cathepsin B (blue) and falcipain-2
(cyan). Catalytic triad residues are shown in the stick representation (yellow: cathepsin B; orange: falcipain-2). Cathepsin B amino acid numbering is
used.
doi:10.1371/journal.pone.0005694.g006
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Due to the conserved overall fold of cathepsin precursors (10),
along with the high degree of structural similarity between these
proteases and mature falcipain-2 (Ca root-mean-square-deviation
between falcipain-2 and cathepsin K is 0.92 A˚; falcipain-2 and
cathepsin L is 0.81 A˚; and falcipain-2 and procaricain is 0.95 A˚),
profalcipain-2 is a good candidate for comparative modeling
analysis. Our model has a good DOPE score, a pairwise atomic
distance statistical potential that has been shown to perform well in
evaluating errors in homology models (17). DOPE is particularly
suited to determine the accuracy of the overall fold of a model.
The DOPE score of the model of falcipain-2 was similar to those
of mature falcipain-2 and procathepsin L, indicating that the
overall fold of our homology model is accurate. A separate model
assessment program, TSVMod, gave essentially the same results.
In our model, residues in the ERFNIN and GNFD motifs were
involved in several interactions important to the stability of the
falcipain-2 prodomain fold (Fig. 5b). Two interactions, Arg185–
Glu221 and Phe214–Trp449/Trp453, appear to be conserved
between falcipain-2 and cathepsin L, with equivalent residues
present in procathepsin L (21). A third interaction, Glu210–Lys403,
represents a unique charged pair interaction, as a Glu is found in
falcipain-2, but not falcipain-3 or most related proteases, replacing
the Gly in the GNFD motif. Side chain packing is the most difficult
part of comparative modeling; however, in this case using the
ERFNIN and GNFD motifs as well as the conserved Phe residues
to guide the alignment resulted in conserved sequences across the
downstream region of the prodomain (Fig. 1), increasing
confidence in our predictions.
Figure 7. Modeled differences between falcipain-2 (a) and cathepsin L (b) prodomain binding to cathepsin B. The model predicts a
helix arrangement in the falcipain-2 prodomain (purple) that prevents steric clashes with the cathepsin B occluding loop (cyan). Phe186 may mediate
this arrangement; in cathepsin K and cathepsin L, Phe186 is replaced by Arg. For cathepsin L (red), there is a large steric clash between the linker
joining the two cathepsin L helices and the space-filled occluding loop (cyan).
doi:10.1371/journal.pone.0005694.g007
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Many cathepsin L sub-family propeptides act in trans to inhibit
related proteases (10). However, selectivity has been observed, and
it has been demonstrated that the prodomains of cathepsin L and
cathepsin K are unable to inhibit cathepsin B (25–27). Explana-
tions for this observation include the following. First, cathepsin B
lacks the ERFNIN motif, so that the protease lacks most of the a2
helix found in cathepsin L sub-family proteases. Second, cathepsin
B contains a large occluding loop insertion, conferring dipeptidase
activity, but preventing propeptides containing the ERFNIN motif
from binding due to a steric clash between the occluding loop and
the prodomain residues connecting a1 and a2 (Fig. 7b).
Interestingly, selectivity for prodomain inhibition was broader
for falcipain-2, as the prodomain of falcipain-2 markedly inhibited
cathepsin B (Fig. 3). Our homology model adds insight to this
observation.
In the model, the interaction of the helices equivalent to
cathepsin L helices a1 and a2 is shifted (Fig. 7a). This shift is
mediated by the presence of an additional aromatic residue in
falcipain-2, Phe186. This residue is part of the hydrophobic
core of aromatic residues that contributes to the helix
interaction in cathepsin L and cathepsin K, normally mediated
by two Trp residues on a1 and the Phe residue in the
ERFNIN motif on a2. In falcipain-2, Phe186 provides
additional stability, allowing a1 to shift across a2 and
eliminating the steric overlap between the prodomain residues
and the cathepsin B occluding loop. In procathepsin L and
procathepsin K, which do not inhibit cathepsin B, Phe186 is
replaced by Arg38 (procathepsin L) and Arg41 (procathepsin K);
arginine is a basic residue that interacts less favorably with the
other hydrophobic residues. (Fig. 7b).
A recent study indicated that a synthetic fifteen residue peptide
(Leu155-Ile169) from a region of the falcipain-2 prodomain
immediately upstream of conserved Phe residues (Phe165 and
Phe168) inhibited falcipain-2 (28). The authors proposed that this
segment plays an important role in inhibition of falcipain-2.
However, inhibition by the peptide was at much lower (10,000
times less) potency than inhibition by our prodomain constructs,
which acted at sub-nanomolar concentrations. In our model, the
Leu155-Ile169 residues form the a1-helix. As noted, these residues
represent an insertion relative to cathepsin L and cathepsin K.
The a1 helix does not appear to actively inhibit falcipain-2, but
rather appears to provide structural stability through an
interaction with the a2 helix. It is thus likely that the full
prodomain inhibits falcipain-2 differently from the small peptide
studied recently (28), as for this peptide to come within the
proximity of the falcipain-2 active site would require replacement
of the a3 helix and a novel fold relative to other papain-family
proteases.
Our work defines the minimum inhibitory region of the
falcipain-2 prodomain. We show that several residues conserved
across cathepsin L sub-family proteases are necessary for this
inhibition, and present a structural model for the interaction of the
falcipain-2 prodomain with both its own mature domain and that
of other proteases. As natural inhibitors of parasite protease
activity, propeptides present a promising basis for design of small
molecules to treat malaria.
Materials and Methods
Reagents
Benzyloxycarbonyl-Leu-Arg-7-amino-4 methyl coumarin (Z-
Leu-Arg-AMC) and Z-Phe-Arg-AMC were from Peptides Inter-
national. Restriction endonucleases and polymerases were from
New England Biolabs. Oligonucleotides were synthesized at the
Biomolecular Resource Center, University of California, San
Francisco, and by Integrated DNA Technologies. The synthetic
peptide was from AnaSpec. All other reagents were from Sigma-
Aldrich or as mentioned in the text.
PCR and Sequencing
All DNA fragments were amplified from the pTOP-FP2
plasmid, which encodes the falcipain-2 gene (6). The sequence
of each construct was confirmed by DNA sequencing at the
Biomolecular Resource Center, University of California, San
Francisco. Portions of the falcipain-2 gene were amplified using
primers specific for each construct (Table S1).
Cloning, Expression, and Refolding of Different
Prodomain Constructs
Amplified DNA fragments were digested with BamHI and
HindIII, ligated into digested plasmids (pRSET-B; Invitrogen) and
used to transform AD (DE3) pLys E. coli (Invitrogen). Cells were
induced with b-D-thio-galactopyranoside, and recombinant pro-
teins were solubilized in 8 M urea, 20 mM Tris-Cl, pH 8.0 at
room temperature for 60 min with gentle shaking. Insoluble
material was separated by centrifugation at 27,000 g for 30 min at
4uC. For the purification of the recombinant protein, the
supernatant was incubated with nickel-nitrilotriacetic acid resin
(Ni-NTA; Qiagen) and purified under denaturing conditions, as
previously described (6). Ni-NTA purified propeptides were bound
to SP-sepharose columns (Amersham Bioscience) and eluted by a
step-wise gradient of 0-1 M NaCl in 8 M urea, 20 mM Tris-Cl,
pH 8.0. The denatured proteins were diluted 100-fold (final
concentration 20 mg/ml) in 100 mM Tris-Cl, 1 mM EDTA,
250 mM L-arginine pH 9.0, refolded at 10–12uC for 20 h, and
concentrated using a 10 kDa cut-off membrane (Millipore) to
10 ml. Insoluble protein was removed using a 0.45 mm syringe
filter (Millipore).
Inhibition of Falcipain-2 by the Prodomain
Inhibitor kinetics were calculated as previously described (15).
In brief, different concentrations of prodomain constructs (2–
50 nM) were pre-incubated with 2 nM falcipain-2 in 100 mM
sodium acetate, 5 mM DTT, pH 5.5 for 10 min at room
temperature. The substrate Z-Leu-Arg-AMC (10 mM) was added,
and fluorescence (excitation 355 nm; emission 460 nm) was
continuously measured for 20 min at room temperature with a
Labsystems Fluroskan Ascent spectrofluorometer. Enzyme con-
centration was determined by titration with the irreversible
inhibitor morpholine urea-phenylanine-homophenylanine fluoro-
methyl ketone. Ki values were determined by nonlinear regression
analysis using PRISM (GraphPad Software).
Inhibition of other Proteases by the Falcipain-2
Prodomain
Substrates were Z-Leu-Arg-AMC (10 mM) for falcipain-2,
falcipain-3, and cruzain; Z-Phe-Arg-AMC (10 mM) for cathepsin
L and cathepsin K; Z-Arg-Arg-AMC (10 mM) for cathepsin B;
Pro-Arg-AMC (10 mM) for cathepsin C; and FITC-casein (8 mg/
ml) for the other studied proteases. For each reaction, 1 mg of
purified falcipain-2 prodomain (or, for controls, no prodomain)
and 2-10 nM of each enzyme were incubated for 10 min in 350 ml
of 100 mM sodium acetate, 5 mM DTT, pH 5.5 (for a-
chymotrypsin and collagenase 10 mM Tris, pH 7.5), substrate
was added, and substrate hydrolysis was monitored as described
above or, for FITC-casein, as previously described (8).
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Experiments were performed on a Jasco J-175 spectropolarim-
eter. Signals were monitored between 195 and 300 nm in 20 mM
sodium phosphate, pH 5.8 at 20uC. Purified proteins were
concentrated (200 mg/ml) using a 10-kDa cutoff Amicon ultra-
concentrater (Millipore) and transferred to the phosphate buffer.
All experiments were performed in a quartz cell of 1 cm path
length (Hellma).
Falcipain-2 Modeling
Falcipain-2 residues 161–484, encompassing the full mature
domain and the C-terminal region of the prodomain, were aligned
with procathepsin L, procathepsin K, and procaricain, at sequence
identities of 20–25% in the prodomain region. 100 homology
models were built based on the crystallographic structures of these
proteins as templates (PDB codes were 1CS8, 1BY8, and 1PCI,
respectively) and the crystallographic structure of mature falcipain-
2 (1YVB), using the standard ‘automodel’ routine of MODEL-
LER-9v4 (16). Models were evaluated with the Z-DOPE statistical
potential (17) and the TSVMod protocol for predicting absolute
model error (18). The model receiving the best Z-DOPE score was
subjected to loop refinement of residues 15–20 (sequence
NKQYNS), restraining the first 14 residues to a helical
conformation, using the ‘loop’ routine of MODELLER-9v4 (19).
Cathepsin-B Modeling
The prodomain of falcipain-2 was modeled in complex with the
crystallographic structure of mature cathepsin B. The same
homology modeling and loop modeling procedures were per-
formed as for falcipain-2, here based on the crystallographic
structures of the prodomain regions of procathepsin L, procathep-
sin K, and procaricain, and the solved structure of procathepsin B
(PDB code 3PBH), as templates. Structural alignments of
procathepsin L and cathepsin B in Fig. 7b were performed with
the SALIGN command of MODELLER-9v4 (20).
Supporting Information
Figure S1 Expression of profalcipain-2 constructs. Different
constructs were expressed in E. coli, and purified as described in
Experimental Procedures. For each construct, 4 mg of protein was
solubilized in SDS sample buffer, electrophoresed in a 12 % SDS-
PAGE gel, and stained with Coomassie blue.
Found at: doi:10.1371/journal.pone.0005694.s001 (0.16 MB TIF)
Table S1 Primers (Forward, F and Reverse, R) used to amplify
DNA encoding the constructs shown are listed. Restriction
endonuclease cleavage sites are in bold type.
Found at: doi:10.1371/journal.pone.0005694.s002 (0.04 MB
DOC)
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